HTG Molecular Diagnostics, Inc., a diagnostic company whose mission is to advance precision medicine, announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on Tuesday, November 12, 2019.
TUCSON, Ariz., Oct. 31, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on Tuesday, November 12, 2019. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
Conference Call & Webcast Details
| Date: | Tuesday, November 12 |
| Time: | 4:30pm Eastern Time |
| Toll Free: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13695647 |
| Webcast: | http://public.viavid.com/index.php?id=136602 |
About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. The company’s mission is to empower precision medicine.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 775-5956
Email: arr@lifesciadvisors.com
